Ritlecitinib

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

7 API Suppliers, 7 Listed Suppliers

DEVELOPMENTS

6 Drug(s) in Development

6 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Reference Price

INTERMEDIATES

1 Suppliers

1 Suppliers

DOSSIERs // Finished Dosage Formulations

1 Dossiers, 1 FDA Orange Book

MARKET PLACE

1 APIs

1 APIs

PATENTS

1 US Patents, 1 US Exclusivities

DIGITAL CONTENT

1 Data Compilations & Company Tracker #PharmaFlow, 5 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

367,105

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 1792180-81-4, Pf-06651600, Ritlecitinib, 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, 2oye00pc25, Pf-06651600 free base

Molecular Formula

C₁₅H₁₉N₅O

Molecular Weight

285.34 g/mol

InChI Key

CBRJPFGIXUFMTM-WDEREUQCSA-N

FDA UNII

2OYE00PC25

Ritlecitinib is an orally available small-molecule inhibitor of tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) with potential immunomodulatory and anti-inflammatory activities. Upon administration, ritlecitinib selectively and irreversibly binds to JAK3 and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of certain pro-inflammatory cytokines and prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. By selectively targeting JAK3, PF-06651600 may spare interleukin (IL)-6 signaling, as well as other JAK1-dependent immunoregulatory cytokines such as IL-10, IL-27, and IL-35, which may offer a safety benefit compared to non-selective JAK inhibitors. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.

1 2D Structure

Ritlecitinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one

2.1.2 InChI

InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1

2.1.3 InChI Key

CBRJPFGIXUFMTM-WDEREUQCSA-N

2.1.4 Canonical SMILES

CC1CCC(CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3

2.1.5 Isomeric SMILES

C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3

2.2 Other Identifiers

2.2.1 UNII

2OYE00PC25

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 1-(5-((7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

2. Pf-06651600

2.3.2 Depositor-Supplied Synonyms

1. 1792180-81-4

2. Pf-06651600

3. Ritlecitinib

4. 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

5. 2oye00pc25

6. Pf-06651600 Free Base

7. 1-[(2s,5r)-2-methyl-5-(7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one

8. Pf06651600

9. Pf 06651600

10. Ritlecitinib?

11. 2-propen-1-one, 1-((2s,5r)-2-methyl-5-(7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)-1-piperidinyl)-

12. Ritlecitinib [inn]

13. Unii-2oye00pc25

14. Ritlecitinib [who-dd]

15. Gtpl9559

16. Chembl4085457

17. Schembl16764638

18. Bcp24778

19. Ex-a2613

20. Example 5 [wo2015083028]

21. Zinc526061581

22. Ccg-267324

23. Db14924

24. Compound 11 [pmid: 28139931]

25. Ac-35550

26. Bp168506

27. Hy-100754

28. Cs-0020243

29. S8538

30. C91239

31. Pf06651600;pf 06651600

2.4 Create Date

2016-02-23

3 Chemical and Physical Properties

Molecular Formula	C₁₅H₁₉N₅O
Molecular Weight	285.34 g/mol
XLogP3	2.1
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	3
Exact Mass	285.15896025 g/mol
Monoisotopic Mass	285.15896025 g/mol
Topological Polar Surface Area	73.9 Å²
Heavy Atom Count	21
Formal Charge	0
Complexity	402
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1